This reports provides a data-driven overview of the current and future competitive landscape in ET therapeutics.
- There will be more than 6,000,000 diagnosed prevalent cases of ET in 2023 in the 16 major markets.
- The marketed drugs space for ET is widely genericized and is dominated by beta-blockers and anticonvulsants.
- R&D activity in ET is very sparse, with no drugs in late-stage development.
- Commercial sponsors dominated the clinical trial development in ET overall, with France emerging as the key country for conducting Phase III trials.
- During the past 24 months, two strategic alliances and one merger & acquisition involving companies developing ET assets were successfully completed.
- Future market players such as AbbVie and Merz Pharma are focusing on developing biologic therapies for ET derived from botulinum toxin.
Scope
GlobalData's ET: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the ET market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ET market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.